YUHAN CORPORATION - Company Intelligence Brief

1. Business Overview

Yuhan Corporation is a South Korean pharmaceutical and healthcare company, trading on the Korean stock exchange under ticker 000100. With a market capitalization of approximately KRW 7.8 trillion (as of filing date), the company operates through consolidated subsidiaries as evidenced by its consolidated financial statements (연결재무제표). Now in its 102nd fiscal year (제 102 기), Yuhan represents one of Korea's longest-established pharmaceutical enterprises.

[TRANSLATION NOTE] Specific business segment details and product lines are not provided in the numerical filing data supplied and would require translation of additional Korean documentation.

2. Financial Trends

Yuhan demonstrates solid revenue growth but concerning profitability trends. Revenue increased 11.2% year-over-year to KRW 2,067.8 billion in FY2024 from KRW 1,859.0 billion in FY2023, marking consistent three-year growth (FY2022: KRW 1,775.8 billion).

However, profitability is deteriorating sharply. Operating income declined to KRW 54.9 billion in FY2024 from KRW 57.0 billion in FY2023, representing an operating margin compression to just 2.7% from 3.1%. More alarming, net income plunged 58.9% to KRW 55.2 billion in FY2024 from KRW 134.2 billion in FY2023. Pre-tax income fell even more dramatically—54.4% to KRW 61.4 billion from KRW 134.8 billion—suggesting significant non-operating headwinds beyond operational challenges.

The balance sheet remains healthy with total assets of KRW 2,942.0 billion against total liabilities of KRW 791.4 billion, yielding a debt-to-equity ratio of approximately 37%. However, total liabilities increased 11.2% year-over-year, outpacing asset growth of 4.6%, with non-current liabilities surging 34.1% to KRW 172.2 billion.

3. Ownership Structure

[TRANSLATION NOTE] Ownership structure and foreign ownership percentage data are not included in the numerical financial statements provided. This information would require translation of the company's separate disclosure documents (주주 현황) typically filed with DART.

4. Key Risks

Margin Erosion Risk: The 58.9% collapse in net income despite 11.2% revenue growth indicates severe cost pressures or one-time charges. The operating margin of 2.7% is razor-thin for a pharmaceutical company, suggesting pricing pressure, R&D expense burdens, or competitive intensity that threatens profitability sustainability.

Non-Operating Income Volatility: The dramatic divergence between operating income (down 3.8%) and pre-tax income (down 54.4%) points to significant non-operating losses or reduced investment income, creating earnings unpredictability beyond core pharmaceutical operations.

5. Investment Consideration

Yuhan offers exposure to a century-old Korean pharmaceutical franchise with stable revenue growth but faces urgent profitability challenges that have halved bottom-line earnings despite top-line expansion, requiring investigation into whether margin compression is temporary or structural.